Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BG-75202

Phase 1Small molecule

BBeOne Medicines

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid MalignancyRecruiting

Myeloid MalignancyPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Myeloid Malignancy

NCT07619287

Q1 2037

Phase 1Recruiting

Advanced Solid Tumors

NCT07222267

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Recruiting·BBeOne Medicines·Phase 1·NCT07222267·86 enrolled

Myeloid Malignancy1 trial

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies

Recruiting·BBeOne Medicines·Phase 1·NCT07619287·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BG-75202. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BG-75202 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BG-75202. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeOne Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBeOne Medicines

Related News